曲前列素製剂全球市场-2022-2029

市场动态

近年来，曲前列素製剂渗透率的提高以及伴随政府举措的各种新技术创新是推动市场增长的因素。

欧洲呼吸学会 (ERS) 报告称，全球 PAH 患病率估计为每百万人 10-52 例，每年范围为 100,000-200,000 人。

在美国，可以获得税收优惠（相当于税收减免等福利的一□□半）、临床研究资助、专利保护和改进的营销权，以加速孤儿药的开发。创新药物和治疗方法的推出增加、政府的积极举措以及医疗保健成本的上涨正在支持市场的增长。

此外，RDA 已经过修订，以创建中央结构（法律制裁）以协调研究并推荐国家研究议程以促进更好的研究和教学。.

血管扩张剂包括前列环素和前列环素类似物，如 Flolan（依前列醇）、Rimodulin/Olenitrum/Taivaso（曲前列素）、Ventavis（伊洛前列素）、Aptravi（司来帕格）和 Beletri（依前列醇）。预计增加的处方和销售量将推动市场增长预测期。这些血管扩张剂在收入方面有望超过内皮素受体拮抗剂（ERA），近年来推出了Uptravi和Ventavis等重磅药物，即将推出潜在的管道药物。

由于主要市场参与者的存在、政府支持措施、先进的医疗保健基础设施以及美国和加拿大 PAH 风险因素的增加，预计北美将在预测期内占据主导地位

一些与脊髓小脑共济失调 (SCA) 相关的副作用预计会阻碍市场增长。

这些药物用于治疗肺动脉高压。这是有益的，但它也有一些副作用，例如脊髓小脑共济失调，一种影响小脑的神经系统疾病，小脑负责协调。这一因素可能会阻碍曲前列素市场的□□增长。

行业分析

曲前列素製剂全球市场根据波特五力、监管分析、供应链分析、流行病学、未满足的需求和产品创新等各种行业因素对市场进行了深入分析。

全球曲前列环素製剂市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 曲前列素药物市场渗透率上升及曲前列素药物市场技术创新
  • 限制因素
    • 与脊髓小脑性共济失调 (SCA) 相关的一些副作用
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 流行病学
• 未满足的需求
• 产品创新

第 6 章按产品类型

• 调节素
• 泰式巴索
• 油橄榄

第 7 章按销售渠道

• 药房
• 诊所中心
• 医院药房
• 零售药房
• 在线

第 8 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 9 章竞争格局

• 主要发展和战略
• 公司份额分析
• 按产品类型进行基准测试
• 值得关注的重点公司列表

第 10 章公司简介

• United Therapeutics
  • 公司概况
  • 按产品类型划分的产品组合和内容
  • 主要亮点
  • 财务摘要
• Novartis
• Teva
• Ascendis Pharma
• Ferrer
• Lee's Pharmaceutical
• Mochida Pharmaceutical
• GlaxoSmithKline
• Pfizer

第11章 曲前列素製剂世界市场-DataM

Market Overview

Treprostinil Drugs Market is expected to grow at a CAGR of 4.5% during the forecasting period (2022-2029).

Treprostinil is a vasodilator/ synthetic analog of prostacyclin that is used for the treatment of pulmonary arterial hypertension (PAH), where Treprostinil dilates (widens) the arteries and decreases the amount of blood clotting platelets in the body. These effects lower blood pressure in the pulmonary artery that leads from the heart to the lungs.

Market Dynamics

In recent time, the rise in the prevalence of treprostinil drugs and various novel technological innovations along with government initiatives are the factors that are increasing the growth of market.

Increasing prevalence of treprostinil drugs and technological innovations in treprostinil drugs market are expected to drive market growth

The European Respiratory Society (ERS) reported that the worldwide prevalence of PAH is ranging from 10 to 52 cases per million and estimated to be in the range of 100,000-200,000 every year.

The presence of favourable government support in the U.S. such as Orphan Drug Act (ODA) 1983 and the Rare Disease Act (RDA) of 2002 to facilitate the development of orphan drugs with benefits including tax incentives (reduced taxes/tax credits equal to half of the development costs), clinical research subsidies, and improved patent protection & marketing rights. Increasing launches of innovative drugs & treatment therapies, favourable initiatives by various governments, and rising spending over healthcare is supporting the market growth.

Besides, RDA amended to create a centralized structure (statutory authorization) for coordinating the research or recommend national research agendas to better facilitate the research & education.

The vasodilators would drive the growth of market during the forecast period due to rising number of prescriptions & sale of prostacyclin and prostacyclin analogs such as Flolan (epoprostenol), Remodulin/Orenitram/Tyvaso (treprostinil), Ventavis (iloprost), Uptravi (selexipag), and Veletri (epoprostenol). These vasodilators will surpass the endothelin receptor antagonists (ERAs) in terms of revenue due to the launch of blockbuster drugs like Uptravi and Ventavis in recent years, and launch of potential pipeline drugs shortly.

The presence of key market participants, supportive government initiatives, and sophisticated healthcare infrastructure, and rising prevalence of risk factors for PAH in the U.S. and Canada would facilitate North America's supremacy throughout the forecast period

Adverse effects associated with some spinocerebellar ataxia (SCA) are expected to hamper the market growth.

These drugs are used for treating pulmonary arterial hypertension. It is beneficial but also have some side effects such as Spinocerebellar Ataxia that is a neurological disorder that affects the cerebellum that is responsible for the coordination. This factor can hamper the growth of Treprostinil drugs market.

Industry Analysis

The global treprostinil drugs market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Epidemiology, Unmet Needs, Product Innovations.

Segment Analysis

Product Type segment is expected to hold the largest market share in global treprostinil drugs market

Based on product type, the global Treprostinil drugs are fragmented into three segments Remodulin, Tyvaso, and Orenitram.

Remodulin: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

Dosage and administration of remodelling (PAH) in patients with NYHA Class II-IV symptoms

a) Initial dose for patients new to prostacyclin infusion therapy: 1.25 ng/kg/min; increase based on clinical response (increments of 1.25 ng/kg/min per week for the first 4 weeks of treatment, later 2.5 ng/kg/min per week).

b) Mild to moderate hepatic insufficiency: Decrease initial dose to 0.625 ng/kg/min.

Tyvaso: It is a follow-on product to Remodulin. As an inhaled formulation of Treprostinil, Tyvaso is better tolerated than continuously and subcutaneously administered Remodulin. United Therapeutics has created a large market niche for its inhaled Treprostinil formulation, Tyvaso, despite the drug being relegated to later lines of therapy and being unavailable outside the US. However, this niche is now under threat from newer, more convenient oral prostacyclins such as Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku), which further possesses a much stronger clinical dataset, as well as United Therapeutics' own oral Orenitram (Treprostinil).

Geographical Analysis

North America region holds the largest market share in the global treprostinil drugs market

North America holds the dominant market share for Treprostinil drug due to increasing prevalence of pulmonary arterial hypertension which is a progressive disease characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), leading to right ventricular failure and death. PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million

Supportive government initiatives for the development of orphan drugs (drugs for rare diseases) are projected to support market growth. For instance, the Rare Disease Act 2002 and the Orphan Drug Act (ODA) 1983 in the U.S. offer incentives, such as tax credits, for the development of orphan drugs. The Orphan Drug Act enables tax credits up to 50% of total R&D cost, funding for R&D, protocol assistance, and waiver in Food and Drug Administration (FDA) fees and clinical tax incentives. These incentives foster pharmaceutical companies to invest in the development of orphan drugs.

The patient-focused Drug Development (PFDD) initiative highlights the power and advocacy for patient care in the U.S. Under these initiatives, meetings were held with a group of people suffering from rare diseases. The agenda of these meetings was to understand disease severity, its impact on patients' lives, and available treatment options.

Competitive Landscape

The major players covered in Treprostinil drugs are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences.

To remain in the forefront of the competitive market, the leading market players are focusing on expanding their geographical presence and investing in product development The adoption of various new strategies by the players help the Treprostinil drugs market to grow at a significant growth rate. For instance, in Sep 2019, New Drug Application of United Therapeutics got approved by U.S. FDA for survey of Trevyent.

Key Companies to Watch

United Therapeutics:

Overview: United Therapeutics is American biotechnology company that is publicly merchandised. They are developing various new technologies for patients that can be life-extending in lung disorders and organ manufacturing fields. This company is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, United States.

Product Portfolio:

Tyvaso inhalation: Tyvaso inhalation is utilized for the treatment of pulmonary arterial hypertension. It widens arteries and reduces the number of blood clotting platelets in the body. This leads to lower blood pressure in the pulmonary artery.

Key Developments: In May 2022, United Therapeutics Tyvaso DPI got FDA approval. This is the first time that a dry powder inhaler got approved for the treatment of pulmonary arterial hypertension.

The global treprostinil drugs market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Increasing Prevalence of Treprostinil Drugs Market and Technological Innovations in Treprostinil Drugs Market
  • 4.1.2. Restraints:
    • 4.1.2.1. Adverse effects associated with Some Spinocerebellar Ataxia (SCA)
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Epidemiology
• 5.5. Unmet Needs
• 5.6. Product innovations

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 6.1.2. Market Attractiveness Index, By Product Type Segment
• 6.2. Remodulin
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Tyvaso
• 6.4. Orenitram

7. By Distribution Channel

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 7.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 7.2. Pharmacies
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Clinic Centers
• 7.4. Hospital pharmacies
• 7.5. Retail pharmacies
• 7.6. Online

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Product Types Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. United Therapeutics
  • 10.1.1. Company Overview
  • 10.1.2. Product Type Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. Novartis
• 10.3. Teva
• 10.4. Ascendis Pharma
• 10.5. Ferrer
• 10.6. Lee's Pharmaceutical
• 10.7. Mochida Pharmaceutical
• 10.8. GlaxoSmithKline
• 10.9. Pfizer

LIST NOT EXHAUSTIVE

11. Global Treprostinil Drugs Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us